Huasen Pharmaceutical: Methylsulfonate Roshagilan tablets have completed domestic production drug record-filing.

Huasen Pharmaceutical announced that the company's product Levodopa Methylephedrine Risperidone tablets have completed the domestic drug production filing, including the paper version of the instructions and electronic version of the drug instructions. This drug is a type B drug covered by national medical insurance, suitable for the single treatment of primary Parkinson's disease patients and as an adjunct therapy to levodopa. This filing is aimed at addressing the trend of population aging, improving information readability and usability, and is expected to enhance the product's market competitiveness and explore new market opportunities. It is not expected to have a significant impact on the company's performance in the short term.